Global Brain Tumor Drugs Market

The lung cancer drugs market consists of sales of lung cancer drugs. Lung cancer is a type of cancer that decreases the ability of lungs to supply oxygen to the bloodstream beacausebecause of uncontrolled growth of tissues in the lung. Some of the possible treatments for lung cancer include surgery, chemotherapy, radiation therapy and targeted therapy. On the basis of the size of the tumor cells, lung cancer is broadly divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). The main types of diseases in lung cancer drugs are small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Small cell lung cancer is a type of lung cancer which grows quickly in the lungs' tissues. Small cell lung cancer has often expanded (metastasized) outside of the lungs by the time a person receives a diagnosis. This malignancy is also more likely to recur after therapy than other types of lung cancer. The different types of drugs include gemzar, paraplatin, taxotere, navelbine, avastin, tarceva, iressa, others and is used in various sectors such as hospitals, clinics, others The global lung cancer drugs market size is expected to grow from $28.45 billion in 2021 to $32.98 billion in 2022 at a compound annual growth rate (CAGR) of 15.9%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The global lung cancer drug market is expected to reach $56.00 billion in 2026 at a CAGR of 14.2%. The rising prevalence rate of lung cancer is a major driver for the lung cancer market. This is mainly because an increase in prevalence and incidence rate of lung cancer cases propels the need for drugs that enable efficient and fast treatment of the disease. It also drives the industry to maintain a strong pipeline of drugs. According to the World Health Organization report, cancer led to around 10 million deaths in 2020, out of which, lung cancer was responsible for the largest number of deaths (1.80 million deaths). Increasing use of biologics and targeted therapies is a major restraint for the lung cancer market. This is because chemical lung cancer drugs come with myriads of side effects and have a toxic effect on the body. Chemical drugs lack cell specificity, i.e., they destroy even the normal body cells along with cancer infected cells. While biologic drugs are highly targeted and work on cancer infected cells only. Biologic drugs are also very efficient with no side-effects. Clinical studies have also found that the probability of success of biologic drugs is much higher than the conventional chemical drugs. For example, Cetuximab, Gefitinib and Afatinib are lung cancer biologic drugs which specifically target only the muted form of tumours and do not destroy the normal body cells. Targeted drug therapy in combination with other therapies is an emerging trend in the lung cancer market. It involves the use of immunotherapy drugs combined with other therapies such as chemotherapy that help in early diagnosis, prevention and treatment of the disease. In this regard, drug manufacturers are developing targeted drug therapies for better diagnosis and treatment of lung cancer. For example, Merck and Co. developed pembrolizumab, which is a drug that helps the immune system to detect and fight cancer cells when used in addition to chemotherapy. This combination therapy showed an improvement in lung cancer status in patients. The drug is a major product of Merck and Co., and is sold under the brand name Keytruda. The FDA's guidelines for lung cancer drugs are mentioned within the Code for Federal Regulations (CFR) title number 21 under part 312, which contains sub-parts from 'A' to 'I'. The sub-part 'E' deals with the procedures designed to push the development, evaluation and marketing of drugs related to therapies aimed to treat persons with life-threatening illnesses such as lung cancer. The sub part 'E' also includes guidelines for monitoring and evaluation of clinical trials of lung cancer drugs and other cancer drugs by agency officials to determine whether new treatments are safe and effective, or better than existing treatments. All drug manufacturers are required to abide to these regulations by the FDA. Hence, regulations such as these would also keep a check on manufacturers of lung cancer drugs. Major players in the lung cancer market are Bristol-Myers Squibb Company, Merck & Co., F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc., GlaxoSmithKlin, Vertiv Co., Sanofi-Aventis, Sun Pharmaceuticals Industries and Celgene Corporation. North America is the largest region in the lung cancer drugs market in 2021. The Middle East is expected to be the fastest growing region in the global lung cancer drugs market during the forecast period. The regions covered in the global lung cancer drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the lung cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global lung cancer drugs market is segmented - 1) By Disease Type: Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC) 2) By End-User: Hospitals, Clinics, Others 3) By Drug: Gemzar, Paraplatin, Taxotere, Navelbine, Avastin, Tarceva, Iressa, Others

The thyroid cancer drugs market consists of sales of drugs that are used to treat thyroid cancer. The thyroid tissue is made up of follicular cells and parafollicular cells in which cancer develops. The types of thyroid cancer include follicular, papillary, medullary, anaplastic and thyroid lymphoma. The main types of thyroid cancer drugs are radioiodine ablation, thyroid stimulating hormone (THS) suppression, chemotherapy, targeted multikinase therapy and others. Radioiodine ablation is a type of radiation therapy that uses radioactive iodine to remove or ablate any healthy thyroid tissue that remains following a thyroidectomy. The different types of drugs include ipilimumab, cabozantinib-s-malate, caprelsa (vandetanib), doxorubicin hydrochloride, lenvatinib mesylate, nivolumab, vandetanib, others and is used in various sectors such as hospitals, oncology clinics, research organizations, others. The global thyroid cancer drugs market size is expected to grow from $0.61 billion in 2021 to $0.72 billion in 2022 at a compound annual growth rate (CAGR) of 18.6%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The global thyroid cancer drug market size is expected to reach $1.33 billion in 2026 at a CAGR of 16.7%. Increasing incidences of thyroid cancer, especially in women is driving the thyroid cancer drugs market. According to the American Cancer Society, women are three times more likely to develop thyroid cancer than men. Thyroid cancer is rising at a fast pace and it is estimated that 52,070 new cases of thyroid cancer will be found in the USA in 2019 and an estimated 2,170 deaths will occur because of the disease. The increase in thyroid cancer can be attributed to exposure to radiation, family history of goiter and some hereditary syndromes. Increasing use of targeted therapies for the treatment of thyroid cancer is acting as a restraint on the thyroid cancer drugs market. Targeted therapies target cancer specific genes, proteins and tissues that promote cancer growth and survival. Targeted therapies are increasingly being used to treat thyroid cancer as thyroid hormone-based treatments including radioactive iodine therapy are not effective against these cancers. For example, Vandetanib (Caprelsa) and Cabozantinib (Cometriq) are targeted therapies used to treat advanced medullary thyroid cancer (MTC). As patients increasingly use targeted therapies for treatment, demand for thyroid cancer drugs is decreasing, affecting market growth. Combination drugs are increasingly being used in the treatment of thyroid cancer as they are more effective and help prevent cancer progression. A combination drug includes two or more active pharmaceutical ingredients (APIs) combined in a single dosage form. These drugs reduce the development of drug resistance and prevent the growth of cancer cells. For instance, the FDA approved the combination of dabrafenib (Tafinlar), a BRAF inhibitor, and trametinib (Mekinist), a MEK inhibitor for the treatment of anaplastic thyroid cancer. Manufacturers of thyroid cancer drugs are governed by regulatory authorities such as the Food and Drug Administration in the USA. For instance, off-label usage of FDA approved drugs for the treatment of cancer requires approval from the FDA. Manufacturers are required to submit a supplemental marketing application called sNDA (Supplemental New Drug Application) to the FDA that approves the drug for prescription. In February 2019, Eli Lilly and Company acquired Loxo Oncology, Inc.for $8 Billion. The acquisition provides Eli Lilly access to a pipeline of investigational medicines like RET inhibitors which are used in thyroid cancer treatment. Loxo Oncology was established in 2013 and is located in Stamford, USA. Major players in the thyroid cancer drugs market are Mylan Pharmaceuticals Inc., Alara Pharmaceutical Corporation, Bristol Myers co., Teva Parenteral Medicines Inc., Jerome Stevens Pharmaceuticals Inc., Baxter International Inc., Abbott Laboratories, App Pharmaceuticals llc., AstraZeneca PLC and GlaxoSmithKline plc. North America is the largest region in the thyroid cancer drugs market in 2021. The Middle East is expected to be the fastest growing region in the thyroid cancer drug market during the forecast period. The regions covered in the thyroid cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the thyroid cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global thyroid cancer drugs market is segmented - 1) By Drug Type: Ipilimumab, Cabozantinib-S-Malate, Caprelsa (Vandetanib), Doxorubicin Hydrochloride, Lenvatinib Mesylate, Nivolumab, Vandetanib, Others 2) By End-User: Hospitals, Oncology Clinics, Research Organizations, Others 3) By Type: Radioiodine Ablation, Thyroid Stimulating Hormone (THS) Suppression, Chemotherapy, Targeted Multikinase Therapy, Others

The prostate cancer drugs market consists of sales of various drugs used for the prevention and treatment of prostate cancer. Prostate cancer is one of the most common types of cancer caused due to uncontrollable development of cells in the prostate gland in men that produces the seminal fluid that nourishes and transports sperm. Some of the possible treatments for prostate cancer include hormonal therapy, chemotherapy, immunotherapy and targeted therapy. The different types of prostate cancer drugs are hormone sensitive prostate cancer and hormone refractory prostate cancer. Hormone-refractory prostate cancer (HRPC) is a kind of prostate cancer that no longer responds to hormone therapy, even newer treatments. The different types of therapies include hormonal therapy, chemotherapy, immunotherapy, targeted therapy and involves various sectors such as hospitals, clinics, others. The global prostate cancer drugs market size is expected to grow from $16.09 billion in 2021 to $17.64 billion in 2022 at a compound annual growth rate (CAGR) of 9.6%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The global prostate cancer drug market is expected to reach $23.95 billion in 2026 at a CAGR of 8.0%. The increasing male geriatric population is a major driver for the prostate cancer drugs market. Prostate cancer is one of the most common types of cancer in men aged above 60. According to the United Nations (UN), there were around 703 million people aged 65 or above globally, accounting for 13% of the global population in 2019. The American Cancer Society's statistics for prostate cancer in the USA states that about 6 prostate cancer cases in 10 are diagnosed in men aged 65 or above, and it is rare for men aged less than 40. Recurrent/non-responsive prostate cancer is major restraint for the growth of the prostate cancer drugs market. This is because recurrent/non-responsive prostate cancer cells lead to recurrence or spread of the cancer after an initial treatment. Prostate cancer can recur locally in the tissue next to the prostate, the surrounding lymph nodes in the pelvis or lymph nodes outside this area, tissues next to the prostate (such as the muscles that help control urination, the rectum, or the wall of the pelvis). The cancer can also travel through the bloodstream and recur in bones or other organs. According to the American Society of Clinical Oncology (ASCO), around 50% to 95% of men in the US with high-risk prostate cancer experience recurrence after localized treatment. The use of combination therapy to treat prostate cancer is an emerging trend in the market. This is mainly because in some cases of prostate cancer, monotherapy has not been effective for the patients. In this regard, companies in the prostate cancer drugs market are investing more in combination therapy for the treatment of prostate cancer. For example, Pfizer announced the results of its Phase 3 PROSPER trial in patients with non-metastatic (M0) Castration-Resistant Prostate Cancer (CRPC), which show that the use of XTANDI (enzalutamide) in combination with androgen deprivation therapy (ADT) significantly reduced the risk of developing metastases or death by 71% compared to using ADT alone. Similarly, other combination therapies such as a combination of radiation therapy and androgen deprivation therapy for men with recurrent prostate cancer, and using chemotherapy drug docetaxel (Taxotere) along with ADT are also being used to treat prostate cancer. The prostate cancer drugs market in the USA is regulated by the FDA which is responsible for approval of new drugs and lays down regulations related to treatment of prostate cancer. For instance, the FDA approved Erleada (apalutamide) for the treatment of prostate cancer that has not spread (non-metastatic), but continues to grow despite treatment with hormone therapy (castration-resistant). This was the first case of FDA-approved treatment for non-metastatic, castration-resistant prostate cancer, and more such approvals are expected to follow in the future. Hence, the regulatory scenario related to prostate cancer drugs will encourage more drug manufacturers to enter the market. In June 2021, Bayer, a Germany based pharmaceutics company acquired Noria Therapeutics Inc. (Noria) and PSMA Therapeutics Inc for an undisclosed amount. With this acquired Bayer will gain exclusive access to a specialized alpha radionuclide investigational drug built on actinium-225 and a small molecule aimed against prostate-specific membrane antigen. PSMA Therapeutics Inc. is a US-based company that specializes in prostate-specific membrane antigen research and Noria Therapeutics Inc. is a radiotherapy firm focused on creating alpha-emitting radiopharmaceuticals for targeted therapeutic and imaging applications in oncology. Major players in the prostate cancer drugs market are Astellas Inc., AstraZeneca plc, Johnson & Johnson, Sanofi S.A, Bayer AG, Roche, Abbott, Pfizer, Norvaris and F. Hoffmann-La Roche AG. North America is the largest region in the prostate cancer drugs market in 2021. The Middle East is expected to be the fastest growing region in the global prostate cancer drug market during the forecast period. The regions covered in the global prostate cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the prostate cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global prostate cancer drugs market is segmented - 1) By Type: Hormone Sensitive Prostate Cancer, Hormone Refractory Prostate Cancer 2) By Therapy: Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy 3) By End-User: Hospitals, Clinics, Others

The skin cancer drugs market consists of sales of skin cancer drugs. Skin Cancer is an unrestricted growth of abnormal skin cells that lead skin cells to proliferate rapidly and form malignant tumors. Skin cancer can be of various types including actinic keratoses, basal cell carcinoma, squamous cell carcinoma or melanoma. Examples of skin cancer drug include 5-FU, Aldara and Efudex. The main types of skin cancer drugs are actinic keratoses (AK), basal cell carcinoma (BCC), squamous cell carcinoma (SCC) and melanoma. Actinic keratoses is a broad, rough skin patch which can turn cancerous. It commonly appears on sun-exposed regions such the face, scalp, backs of the hands, and chest. It is especially common in fair-skinned persons. Solar keratosis and senile keratosis are two terms for the same condition. The different classes of drugs include chemotherapy, immunotherapy, targeted agents & other drugs and is used in various sectors such as hospitals, cancer research centers, clinics. The global skin cancer drugs market size is expected to grow from $2.62 billion in 2021 to $3.06 billion in 2022 at a compound annual growth rate (CAGR) of 17.0%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The global skin cancer drug market is expected to reach $5.39 billion in 2026 at a CAGR of 15.2%. Significant rise in prevalence of skin cancer is driving the demand for the drugs for Skin Cancer. To treat such high cases of skin cancer, more number of new innovative skin cancer drugs is being manufactured. According to the American Academy Of Dermatology, in 2019, there were 192,310 new cases of Melanoma type skin cancer. Additionally, non-invasive type skin cancer count could rise to 95,830 and 96,480 invasive skin cancer could be diagnosed in US in 2019. According to the American Academy Of Dermatology, each year roughly around 3 million Americans get diagnosed by skin cancer. This is boosting the demand for skin cancer drugs and thus driving the market. Increasing use of biologics and targeted therapies is acting as a restraint in the skin cancer drugs market. The targeted therapies drugs targets melanoma cells only. The chemical drugs attack any fast-dividing cells while targeted therapies only attack the skin cancer causing melanoma cells. Thus, doctors are preferring targeted therapies to treat skin cancer. This is expected to affect the sales of conventional chemical skin cancer drugs and limit the growth of the market going forward. Companies in the skin cancer market are increasingly looking for strategic alliances with other companies in the market. Strategic alliances help companies to enhance their R&D capability, expedite the development process of new drugs and reinforce competitive position in the market. For example, Leo Pharma has formed a strategic alliance with PellePharm, to develop a drug to treat a very rare form of skin cancer called Gorlin syndrome. MorphoSys and LEO Pharma strategically worked together to develop antibodies pertaining to the treatment of skin cancer. Pfizer had entered into a strategic alliance with Merck KGaA to manufacture an innovative drug pertaining to skin cancer. The European Medicines Agency (EMA) is the regulatory body that evaluates and supervises the production and sales of medicines for safety and benefit of the customer, in the European Union Region. The manufacturers of skin cancer drugs and all other drugs need to comply with manufacturing practices specified by the EMA. The EMA also regulates and supervises the drug quality, check for the intended use of the drug and whether the drug is meeting the requirement of clinical trial. The EMA also educates the patients regarding the risks associated in taking skin cancer drugs such as Tafinlar and Opdivo, what are the safety measures that are needed to be taken while consuming the drug, benefits of the drug and all other relevant information pertaining to such drugs. In April 2019, Bristol-Myers Squibb acquired Celgene for $74 billion. This acquisition would help Bristol-Myers Squibb to widen its portfolio of drug in skin cancer market. This acquisition would also help Bristol-Myers Squibb to expedite the development of new innovative drugs which are in the early stages of drug pipeline. Celgene is an innovative biotechnology company that manufactures and develops cancer drugs. Celgene was founded in 1986 and is headquartered at Summit, New Jersey, United States. Major players in the skin cancer drugs market are Novartis AG, Bristol Myers Squibb, Eli Lilly, Meda, Sun Pharmaceutical Industries Ltd, Roche, Aqua Pharmaceuticals, Bausch Health, GlaxoSmithKline PLC and Pfizer Inc. North America is the largest region in the skin cancer drugs market in 2021. The Middle East is expected to be the fastest growing region in the global skin cancer drug market during the forecast period. The regions covered in the global skin cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the skin cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global skin cancer drugs market is segmented - 1) By Type: Actinic Keratoses (AK), Basal Cell Carcinoma (BCC), Squamous Cell Carcinoma (SCC), Melanoma 2) By End-User: Hospitals, Cancer Research Centers, Clinics 3) By Drug Class: Chemotherapy, Immunotherapy, Targeted Agents and Other Drugs

The blood cancer drugs market consists of sales of drugs to treat all types of blood cancers. The blood cancer drugs market excludes biologics and includes establishments that produce drugs used in chemotherapy, surgery and radio therapies for treating leukaemia, lymphoma, and myeloma. The main types of blood cancer drugs are leukemia, and lymphoma. Leukemia is a blood-forming tissue cancer that affects the bone marrow and lymphatic tract. The different types of drugs include rituaxan/mabthera (rituximab), gleevac/glivec (imatinib), revlimid (lenalidomide), velcade (bortezomib), tasigna (nilotinib), pomalyst (pomalidomide), vidaza (azacitidine), kyprolis (carfilzomib), adcetris (brentuximab vedotin), others and involve various treatment approaches such as key findings, chemotherapeutic, mabs/targeted therapies, immunotherapeutic. The global blood cancer drugs market size is expected to grow from $54.83 billion in 2021 to $61.26 billion in 2022 at a compound annual growth rate (CAGR) of 11.7%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The global blood cancer drug market size is expected to reach $89.75 billion in 2026 at a CAGR of 10.0%. The blood cancer drugs market is being driven by the growing death incidences and increasing prevalence of blood cancer cases across the globe. Different types of blood cancers such as lymphoma, leukaemia, myeloma and others have different risk factors where some can be controlled or prevented through drug therapies and others may lead to death. According to Bristol-Myers Squibb Company report, over 1.85 million new blood cancer cases are expected to be diagnosed across the globe in 2040, out of which 918,872 cases are from lymphoma, 656,345 from leukaemia, and 275,047 cases myeloma. Furthermore, the report estimated, in 2040, the approximate number of deaths worldwide due to blood cancer will be 1,100,000. In 2019, more than 387,000 people are living with leukaemia in the United States and 68,000 deaths resulted from blood cancer. According to national cancer institute, the deaths due to blood cancer reached around 22,840 in 2019. The increasing deaths and increasing incidence of blood cancer cases globally drives the blood cancer drug market. Drug approval involves series of research stages and regulatory approvals that are often expensive. Drug approval process include about four phases of clinical trials and various stages of screening process with the regulatory body such as FDA. The costs of failed clinical trials are also high as clinical trial phases involves huge investments. According to Tufts Centre for the Study of Drug Development, the cost of bringing a new drug from its conception to shelves is about $2.7 billion. Thus indicating that the high drug approval costs hinders the growth of the blood cancer drugs market. Companies in the blood cancer drugs market are increasingly investing in technologies such as artificial intelligence (AI) to save time and reduce research and development costs. AI is the simulation of human intelligence processes by machines, especially computer systems, which has the potential to surpass human intelligence levels. This technology helps to analyse large sets of chemical and biological data to identify potential drug candidates with higher success rates and at a quicker pace when compared to human analysis. The technology also helps in speeding up the patient recruitment process by matching blood cancer patients with the most relevant clinical trials, thus lowering clinical trial costs. Major blood cancer drug manufacturers such as Roche, Pfizer and Johnson and Johnson have already invested in AI technologies to reduce time taken and costs incurred for drug development. For instance, Johnson and Johnson entered into an agreement with BenevolentAI, a UK-based artificial intelligence company (start-up), to mine data for designing new blood cancer drugs. The Food and Drug Administration (FDA) is a federal agency regulating the blood cancer drugs market. In June 2019, FDA declined to approve Daiichi Sankyo’s leukaemia drug for blood cancer treatment. Daiichi Sankyo, a global pharmaceutical company developing, importing and marketing pharmaceutical products received a rejection notice on its drug - quizartinib used for treating adults with a type of blood cancer. The rejection of drug was due to the negative impact caused after the intake which resulted in FDA's statement saying faulty application for blood cancer treatment in an internal review. To avoid the incidences caused by such medicines in treating medical conditions such as blood cancer, FDA has declined to the approval. In 2019, Eli Lilly, a US-based pharmaceutical company, acquired Loxo Oncology, a cancer-focused biotechnology company for $8 billion. This acquisition of Loxo Oncology provides Lilly with a promising pipeline of investigational medicines such as oral RET inhibitor, oral BTK inhibitor and others. The deal would enable Lilly to attain strong patent on Loxo's genetically based approach to treat cancer. Loxo Oncology, is a biopharmaceutical company, developing and selling medicines for patients with genetically defined cancers. The company focuses on building small molecule cancer drugs for genetically defined cancer patients. The company was founded in 2013 and is headquartered in Stamford, Connecticut, USA. Major players in the blood cancer drugs market are Amgen Inc., AstraZeneca PLC, Bayer AG, Celgene Corporation, Eli Lilly, Johnson & Johnson, Novartis, Pfizer Inc, AbbVie Inc. and Takeda Pharmaceutical Company Ltd. North America is the largest region in the blood cancer drugs market in 2021. The Middle East is expected to be the fastest growing region in the global blood cancer drug market during the forecast period. The regions covered in the global blood cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the blood cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global blood cancer drugs market is segmented - 1) By Blood Cancer Type: Leukemia, Lymphoma 2) By Drug: Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), Others 3) By Treatment Approach: Key Findings, Chemotherapeutic, MAbs/Targeted Therapies, Immunotherapeutic

The bladder cancer drugs market consists of sales of bladder cancer drugs. Bladder cancer is cancerous tissue that occurs on the lining of the bladder. These cancerous tissues are also called tumors and have the potential to spread to other nearby cells and tissues if not treated soon. The bladder cancer market consists of treatments of bladder cancer types such as urothelial carcinoma, squamous cell bladder cancer, adenocarcinoma and others. The main types of bladder cancer drugs are non-muscle-invasive bladder cancer and muscle-invasive bladder cancer. NMIBC (non-muscle invasive bladder cancer) is cancer that develops in the tissue that lines the bladder’s inner surface. There is no involvement of the bladder muscle. The different applications include low-grade tumors, high-grade tumors and distributed through various channels such as hospital pharmacy, retail pharmacy, others. The global bladder cancer drugs market size is expected to grow from $1.98 billion in 2021 to $2.35 billion in 2022 at a compound annual growth rate (CAGR) of 19.1%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The global bladder cancer drug market size is expected to reach $4.45 billion in 2026 at a CAGR of 17.3%. The number of bladder cancer cases has been on the rise. Factors such as unhygienic workplace exposures, increase in smoking habits and consuming water that contains Arsenic increases the chances of blood cancer. According to American Cancer Society, there were 81,400 new cases of bladder cancer in 2020 out of which a total of 62,100 cases were in men and 19,300 cases in women. This increased incidence of bladder cancer increases the demand for bladder cancer drugs, contributing to the growth of the market. Increasing use of biologics and targeted therapies restrains the bladder cancer drugs market. Biologic therapy uses a body’s immune system to fight cancer rather than chemical drugs which reduces the body’s immune power. For instance, FDA cleared targeted therapy, Tecentriq, a first product in its class (PD-1/PD-L1 inhibitors) approved to treat bladder cancer. The advantages of biologics drugs and targeted therapies over conventional chemical drugs might negatively influence the market. Major organizations are investing on the research to utilize nano-technology as a means to deliver drugs into the human body. nanotechnology is the design, characterization, production, and application of devices, structures and systems by controlled manipulation of size and shape at the nanometer scale. This method of delivery helps doctors to offer a simple and effective way of treating bladder cancer in their patients, due to the fact that the nanoparticles used in the treatment can attack the cancerous cells directly without harming the surrounding cells. For instance, in February 2019, the Center for Drug Research And Development in Canada has pledged a $1.2 million investment in Sitka biopharma to help with development activities for clinical trials of STK-01, a product to treat bladder cancer using nanotechnology. The bladder cancer drugs market is regulated by government agencies such as European Medicines Agency (EMA), USFDA (the US food and drug ministration), and others which lay down policies and guidelines that a manufacturer should follow. For instance, in the USA, FDA has formulated three main programs for expediting drugs that could be used to treat serious conditions, namely the fast-track program, the breakthrough drug program, and the accelerated approval program. Though these three programs are used in expediting the approval of drugs, there subtle differences. Fast track status is given to a drug that can treat a serious condition and clinical/non-clinical data prove its potential to cater to unmet medical needs. Breakthrough therapy status is given to a drug that can treat a serious condition and there is proper clinical evidence of it being better than available treatments. Accelerated approval status is given to a drug that has breakthrough therapy status along with a surrogate endpoint that can predict its effectiveness. A surrogate endpoint is an indicator or sign that can be used to tell if a treatment method is effective or not. For example, in cancer treatments a shrinking tumor can be used as an indicator of cancer treatment effectiveness than checking for time of tumor survival. Surrogate endpoints are used in clinical trials to save time and is especially used in the fast expedition of life-saving drugs. FDA expedites drugs under all three programs within 60 days of filing a request for consideration. In April 2019, Bristol-Myers Squibb Company, an American pharmaceutical company got the approval to acquire Celgene corporation for $74 billion. The transaction helps Bristol-Myers acquire a bigger market share of immuno-oncology drugs including bladder cancer drugs in the USA and compete with its competitors. Celgene corporation, a company that develops medicines for cancer and inflammatory disorders, was founded in 1996 and has its headquarters in the USA. Major players in the bladder cancer drugs market are Pfizer, Celgene Corporation, Eli Lilly, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Sanofi, Hoffmann-La Roche, Novartis International and Johnson & Johnson. North America is the largest region in the bladder cancer drugs market in 2021. The Middle East is expected to be the fastest growing region in the bladder cancer drug market during the forecast period. The regions covered in the bladder cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the bladder cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global bladder cancer drugs market is segmented - 1) By Type: Non-Muscle-Invasive Bladder Cancer, Muscle-Invasive Bladder Cancer 2) By Application: Low-Grade Tumors, High-Grade Tumors 3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Others

The pancreatic cancer drugs market consists of sales of drugs used to treat pancreatic cancer. Pancreatic cancer is a disease caused by the unrestrained growth of cells in the pancreas, thus disrupting the production of digestive juices and hormones responsible to regulate the blood sugar level in the body. This abnormal growth of cells leads to tissue lumps referred as tumors. The presence of tumors hinders the normal pancreas functioning. The main types of pancreatic cancer drugs are endocrine pancreatic cancer and exocrine pancreatic cancer. A pancreatic cell which generates enzymes that are released into the small intestine is known as an exocrine pancreatic cell. These enzymes aid in the digestion of food as it moves through the digestive tract. The different types of drugs include afinitor, erlotinib, hydrochloride everolimus, 5-fu, flurouracil, gemcitanine, abraxane and is used in various sectors such as hospitals, clinics, others. The global pancreatic cancer drugs market size is expected to grow from $3.45 billion in 2021 to $3.71 billion in 2022 at a compound annual growth rate (CAGR) of 7.5%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The global pancreatic cancer drug market size is expected to reach $4.67 billion in 2026 at a CAGR of 5.9%. The increasing prevalence of pancreatic cancer is expected to drive the growth of the pancreatic cancer drugs market. With the rise in number of pancreatic cancer cases, the demand for drugs is expected to increase as well, which will drive the growth of the market. The number of cancer cases have increased mainly due to ageing population and increase in number of people suffering from obesity. For instance, according to the American Cancer Society, in 2021, around 60,430 people (28,480 women and 31,950 men) are diagnosed with pancreatic cancer and approximately 48,220 people (22,950 women and 25,270 men) died from this cancer. One of the major restraints of the pancreatic cancer drugs market is the inadequacy of results given by the drugs at the time of treatment. The inadequacy in the result is due to aggressive nature of the pancreatic cancer as the cancer cells break away from main tumor and enters into blood stream, spreading the cancer cells throughout the body in a short period of time therefore this cancer is usually discovered late. The late discovery of pancreatic cancer affects the efficacy of the drugs because the drugs can work effectively only if cancer is detected timely in an early stage itself (In the stage 1 or stage 2 where cancer cells are limited to where the tumor is present). Therefore, the mortality rate for pancreatic cancer is very high. For instance, in April 2019, in Japan out of the total number of people diagnosed for pancreatic cancer, only 5-10% survived. The concept of combination therapy over monotherapy is one of the latest ongoing trend in the pancreatic cancer drugs market. Major players in the market understand that the combination of two or more drugs is a suitable way to increase the efficacy of the drugs and thus increasing the rate of survival of patients being diagnosed with pancreatic cancer. Some of the companies investing in the combination therapy are Rafael Pharmaceuticals announced initiation of Pivotal Phase 3 Trial (AVENGER 500) of CPI-613 (devimistat) in combination with Modified FOLFIRINOX as first line treatment for patients with Metastatic Pancreatic Cancer and Apexigen, Inc., a clinical-stage biopharmaceutical company, announced the presentation of new clinical data on APX005M in combination therapy in patients with metastatic pancreatic cancer in March 2019. As per the regulations laid down by the Food and Drug Administration (FDA), any pancreatic drug which seeks approval by FDA has to clear three phases of clinical trial process. The drug should be proved to be safe and promising at each phase before moving on to the next one, in order to become eligible for approval from the Food and Drug Administration (FDA). The European Medicine Association has laid down guidelines for clinical development of pancreatic drugs including setting of standards for patient's diet with respect to the drug, and establishing criteria for primary efficacy of the drug during the development stage in the clinical trial process, thereby ensuring that effectiveness of the drugs on cancer cells is established while the drug is still in the development stage in clinic. In February 2019, Eli Lilly and Company, a US-based company that develops, manufactures, and markets pharmaceutical products worldwide, acquired Loxo Oncology, Inc. for $8 billion. With this acquisition, Eli Lilly will be able to expand its portfolio into the market for precision medicines which will be able to target pancreatic cancer caused by specific gene abnormalities. Loxo Oncology, Inc., a US-based company focuses on building small molecule cancer drugs for genetically defined patient subsets. Major players in the pancreatic cancer drugs market are Eli Lilly and Company, F. Hoffman LA Rouch, Clovis Oncology, Pfizer, Novartis AG, Amgen, Celegene Corporation, AB Science, GlaxoSmithKline and Abbvie Inc. North America is the largest region in the pancreatic cancer drugs market in 2021. The Middle East is expected to be the fastest growing region in the pancreatic cancer drug market during the forecast period. The regions covered in the pancreatic cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the pancreatic cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global pancreatic cancer drugs market is segmented - 1) By Type: Endocrine Pancreatic Cancer, Exocrine Pancreatic Cancer 2) By End-User: Hospitals, Clinics, Others 3) By Drug: Afinitor, Erlotinib, Hydrochloride Everolimus, 5-FU, Flurouracil, Gemcitanine, Abraxane

The cancer biologics market consists of sales of cancer biologics. Cancer biologic drugs are the products that are produced from living organisms or contain components of a living organisms. Biologic drugs include a wide variety of products which are derived from human, animal or microorganisms by using biotechnology. The main types of cancer biologics are monoclonal antibodies, vaccines, cell and gene therapy, others. Monoclonal antibodies are created by cloning a single white blood cell. Every subsequent antibody generated in this manner may be traced back to a single parent cell. It is used in non-small cell lung cancer, prostate cancer, breast cancer, acute myeloid leukemia, lymphoma, multiple myeloma, ovarian cancer, colorectal cancer, gastric cancers, others and distributed through various channels such as hospitals, clinics, others. The global cancer biologics market size is expected to grow from $76.46 billion in 2021 to $86.64 billion in 2022 at a compound annual growth rate (CAGR) of 13.3%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The cancer biologics market is expected to reach $129.05 billion in 2026 at a CAGR of 10.5%. Rising prevalence of chronic diseases is one of the major factors driving the cancer biologics market growth. Chronic disorders are the diseases which persists over a long period of time and hinder the health of people with disabilities and cancer is one of the common chronic diseases. The most common cancers are breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, melanoma of the skin, bladder cancer, non-Hodgkin lymphoma, kidney and renal pelvis cancer, endometrial cancer, leukemia, pancreatic cancer, thyroid cancer, and liver cancer. According to World Health Organization (WHO), in 2020 chronic diseases accounted for 75% of deaths globally. Therefore, the rising prevalence of chronic diseases is expected to drive the growth of the cancer biologics market over coming years. The cancer biologics market is being restrained by the adverse effects associated with the use of cancer biologics. Biologic drugs are administered by injection or infusion as they are proteins which are quickly digested and inactivated if given by mouth so they can cause injection site reactions or infusion reactions. Moreover, the adverse effects of the biologics vary from common side effects such as allergic reactions and diarrhoea to serious adverse effects such as low blood pressure, hepatitis and hypothyroidism. For instance, according to a study conducted by NCBI, biological agents are essential additions to chemotherapy for GI malignancies that leads to enhanced survival response rates but these additions also bring some unique adverse reactions to the patients. Companies in the cancer biologics market are developing predictive biomarkers which help the physicians to decide the treatments for their patients by utilizing physiological biomarkers for predicting the performance. Predictive biomarkers study tumor growth in patients by analyzing the major etiological factors as the cancer etiology differs from patient to patient. Moreover, these biomarkers not only aid in the early detection of cancer but also help in deciding the cost-effective treatment regimens, especially for the biologics based on gene therapy. According to FDA approval process of new cancer treatment and biological products, the application for the approval should include all relevant data available from clinical studies, including negative results as well as positive findings. Data can come from pharmaceutical company sponsored clinical trials intended to test the safety and effectiveness of a new use of a product, or from a number of alternative sources. In May 2019, Evotec SE, drug discovery and development solutions provider acquired Just Biotherapeutics, Inc. for $90 million. The acquisition will help Evotec's business to grow into offering the biologics into the therapeutic areas such as oncology. Just Biotherapeutics is a US-based unique technology company that integrates highly synergistic scientific expertise and ML driven technologies for development and manufacturing of biologics at highest standards. Major players in the cancer biologics market are AbbVie Inc., Hoffman-La Roche, GlaxoSmithKline, Eli Lilly and Company, Amgen Inc., Bristol-Myers Squibb Company, Johnson & Johnson, Merck & Co.Inc., Novartis and Pfizer. North America was the largest region in the cancer biologics market in 2021. The Middle East is expected to be the fargest growing region in the forecast period. The regions covered in the cancer biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cancer biologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global cancer biologics market is segmented - 1) By Type: Monoclonal Antibodies, Vaccines, Cell and Gene Therapy, Others 2) By Application: Non-Small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Ovarian Cancer, Colorectal Cancer, Gastric Cancers, Others 3) By Distribution Channel: Hospitals, Clinics, Others